Kali Therapeutics Signs Deal with Sanofi to Develop Autoimmune ...

Sanofi pays $180m for rights to Kali autoimmune drug

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

Sanofi inks $1B autoimmune deal with Kali Therapeutics

Kali Therapeutics signs deal with Sanofi to develop autoimmune ...

Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics - European Biotechnology Magazine

Sanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics' next-generation tri-specific T-cell engager targeting B cell-mediated autoimmune diseases. The post Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics appeared first on European Biotechnology Magazine.

Kali, Sanofi sign licence agreement for KT501 autoimmune disease antibody

Sanofi and Kali Therapeutics have signed an exclusive global licence agreement for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases.

A California startup wins $180M in support as Sanofi rebuilds presence in T cell engagers

Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in a large upfront deal that ...